Rezolute To Participate In Upcoming Investor Conferences
Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Date: November 9-11, 2026
Fireside Date/Time: Monday, November 9th at 9:00am ET
Event: Jefferies London Healthcare Conference
Date: November 16-19, 2026
Fireside Date/Time: Thursday, November 19th at 1:00pm GMT
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visitContacts:
Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
...
508-272-6717
Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
...
336-608-9706
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment